Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / HEPA - Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

HEPA - Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

Hepion Pharmaceuticals Inc.
  • Hepion Pharmaceuticals is a biopharmaceutical company focused on drug therapy treatment for chronic liver diseases in the US.
  • It's currently developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.
  • Today we talk to CEO Dr. Robert Foster about the trials, differences between NASH and NAFLD and the decision to focus on cyclophilins.

For further details see:

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...